Pharmaceutical Technology

APRIL 6, 2023

Biotheryx and Incyte have signed an agreement for identifying and developing targeted protein degraders for historically undruggable oncology targets. Biotheryx will also receive up to $347m in potential future regulatory and commercial milestone payments, along with tiered single-digit royalties on net product sales across the globe.

Protein 130

Protein Development Sales Production 130

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Discover the top API protein and peptide companies in contract marketing. Technologies in the delivery of peptides and proteins. They are promising therapeutics for the treatment of a variety of metabolic and oncological disorders.

Protein 100

Protein Marketing Manufacturing Reagent 100

XTalks

MARCH 26, 2025

In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. billion in sales, marking a turnaround from the prior years losses.

Packaging 105

Packaging Packaging Protein Production 105

Pharmaceutical Technology

MAY 9, 2023

They will also use the metagenomic sequence database of Ginkgo Bioworks which comprises more than three terabases of sequence data and over two billion protein sequences from various microbes. The database offers access to several structurally bioactive molecules that will help to quickly identify lead molecules and develop new treatments.

Development 261

Development Protein Sales Production 261

Pharmaceutical Technology

APRIL 21, 2023

The company is also expected to receive royalty payments on sales of the product. This will create high-quality VHH libraries for use against any target protein. Twist’s VHH libraries use new techniques to combine synthetic and natural approaches for increasing the diversity of each library up to ten billion.

Antibody 264

Antibody Licensing Licensing Protein 264

Pharmaceutical Technology

JUNE 21, 2023

Hemgenix works by dosing a patient with an engineered adeno-associated virus (AAV), containing the gene responsible for producing a protein called factor IX. This protein helps to form blood clots and stop bleeding, with haemophilia B arising when the body is partially or completely unable to produce it.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

XTalks

JUNE 20, 2022

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid. billion in global sales by 2026.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

Pharmaceutical Technology

DECEMBER 23, 2022

As per the prior and expanded agreements, ProQR is entitled to get research, development and commercialisation milestone payments totalling up to nearly $3.75bn, apart from tiered royalty payments on sales of products. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Pharmaceutical Technology

DECEMBER 8, 2022

The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K. Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Pharmaceutical Technology

JUNE 29, 2022

Specialty enzymes are proteins that can act as very specific biocatalysts to accelerate reactions and produce the desired target molecule in pharmaceuticals,” explains Kristoffer Laursen, Head of R&D at Novo Nordisk Pharmatech. “In In the evolving biotechnology industry, enzymes are important process aids.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Pharmaceutical Technology

JUNE 13, 2023

Ziftomenib targets the menin-KMT2a protein-protein interaction that may occur in patients with KMT2ar or NPM1m genetic alterations. The aberrant protein complex is essential for regulating leukaemia-promoting gene expression. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029.

Gene Expression 130

Gene Expression Protein Sales Genetics 130

Roots Analysis

SEPTEMBER 9, 2024

Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

XTalks

JANUARY 29, 2025

Related: Eli Lillys Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi Leqembi was first approved in 2023 as a monoclonal antibody targeting amyloid-beta protofibrils and plaques proteins that cause brain cell damage and cognitive decline in Alzheimers disease.

FDA Approval 66

FDA Approval Antibody Sales Protein 66

Pharmaceutical Technology

JULY 6, 2022

In a press statement, CureVac said: “CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.”.

Vaccine 182

Vaccine Vaccination Gene Therapy Engineer 182

Pharmaceutical Technology

APRIL 25, 2023

Reinstating CFH function by employing the sCFH protein could restore normal complement regulation and minimise retinal injury that manifests as progressive geographic atrophy (GA). Aevitas will receive the payment as potential late-stage development, regulatory and sales milestones.

In-Vivo 130

In-Vivo In-Vitro Sales Engineer 130

XTalks

MAY 15, 2023

Fairlife milk boasts 50 percent higher levels of protein and calcium while containing 50 percent less sugar compared to traditional milk, while also being lactose-free. This process enables the extraction of targeted nutrients such as protein and calcium while isolating fats and sugars from the milk. Fair” Life?

Protein 98

Protein Sales Branding Containment 98

XTalks

NOVEMBER 17, 2022

Despite declining sales and category slowdown, food giant Nestlé is still keen on investing in plant-based alternatives to traditional meat. The previously fast-growing plant-based meat segment saw sales growth flatten last year after surging 45 percent in 2020. Related: Why Plant-Based Meat Sales are Stagnant in 2022.

Branding 98

Branding Sales Protein Production 98

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.

Research 130

Research Antibody Sales Development 130

pharmaphorum

DECEMBER 4, 2020

Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

XTalks

APRIL 1, 2025

Through RNA silencing, it targets the expression of antithrombin, a protein that inhibits blood clotting. Moreover, Qfitlia, an siRNA therapy that blocks target protein expression at the RNA level, requires dosing only once every other month, compared to Alhemos daily and Hympavzis weekly dosing. In 2024, it registered sales of $4.9

FDA Approval 59

FDA Approval RNA Clinical Trials Clinical Trials 59

Pharmaceutical Technology

OCTOBER 12, 2022

Additionally, the company will receive tiered royalties from mid-single to low double-digits on worldwide net sales. The pipeline of the company includes several selective small-molecule compounds that target proteins which are recognised to be fundamental pathology drivers in human diseases.

Development 130

Development Protein Engineer Drugs 130

World of DTC Marketing

APRIL 11, 2021

Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome. However, the continued study of the virus was shelved because of the lack of funding. Do Lockdowns Work?

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. Tiered royalties on net sales are also included in the deal. FAP-2286 is being investigated as a peptide-targeted radionuclide therapy.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Pharmaceutical Technology

APRIL 11, 2023

The company stated that azithromycin tablets generated annual sales of $20m in the US. The vaccine, which generates the SARS-CoV-2 viral spike protein on administration, induces the immune system’s cellular and humoral arm-mediated immune response.

FDA Approval 130

FDA Approval Drugs Immune Response Manufacturing 130

Pharmaceutical Technology

MAY 4, 2023

Kamada stated that the technology transfer supplement includes the manufacture of an upstream protein solution undertaken by Prothya Biosolutions at its facility in Belgium. In 2022, the therapy generated $23m in sales. It is claimed to be the only immunoglobulin (IgG) product to receive FDA approval for this indication.

FDA Approval 130

FDA Approval Manufacturing Production Protein 130

XTalks

DECEMBER 4, 2023

Ripple pea milk stands out for its yellow pea-based milk and protein shakes. This technology effectively removes undesirable elements like color and flavor from standard plant protein isolates. The result is “ Ripptein ,” a uniquely neutral-tasting protein suitable for high-quantity inclusion in both food and beverages.

Protein 105

Protein Branding Production Marketing 105

Pharmaceutical Technology

JULY 1, 2022

Twist will be entitled to receive an upfront payment, annual maintenance fees, further payments on successfully meeting clinical and regulatory milestones and royalty payments on product sales. VHH antibodies’ small size permits them to reach targets that conventional antibodies cannot with strongly attaching affinity.

Antibody 147

Antibody Development Licensing Licensing 147

XTalks

JANUARY 29, 2021

Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. Merck’s Keytruda ($7.2B) and BMS’s Opdivo ($1.8B) hold the number 2 and number 11 spots, respectively, in annual sales of the top oncology products. Herceptin (Trastuzumab) and Mabthera (Rituximab).

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

pharmaphorum

MARCH 19, 2021

Now the Ireland-based firm said that early data from studies shows the system can detect and identify the COVID virus S-Protein in quantities at 40 femtograms per millilitre at close to 100% specificity. A femtogram is 0.000000000000000001 kilograms. It has licensed in a patented breathalyser, the analysts noted.

Contamination 145

Contamination Clinical Trials Clinical Trials Protein 145

XTalks

JANUARY 14, 2021

A source of protein, fat and fiber, mealworms also show promise as a sustainable source of food for generations to come. The insects can also be used as an alternative source of protein for animals and its waste is ideal as organic fertilizer. They are not, however, widely consumed in the west or Europe. billion by 2025.

Allergies 97

Allergies Protein Containment Sales 97

XTalks

MARCH 18, 2025

By inhibiting this protein, povorcitinib reduces the inflammatory signals that contribute to abscess and nodule formation. Janus kinase one (JAK1) plays a central role in the signaling pathways of several inflammatory cytokines. On March 17, 2025 , Incytes stock closed at $62.01, down 8.62% from the previous close of $67.86.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

AUGUST 27, 2020

This includes pea protein, which is one of the most environmentally friendly sources of plant-based protein because peas require little land and water and can be grown in cold climates. The pea protein also contains all the essential amino acids and is free of artificial colorings and preservatives.

Marketing 98

Marketing Protein Production Sales 98

Pharmaceutical Technology

MARCH 23, 2023

Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccine Vaccination In-Vivo 147

Pharmaceutical Technology

AUGUST 2, 2022

Under the deal, the companies will develop small molecules that can modulate new G protein-coupled receptor (GPCR) targets linked to neurological diseases. Additionally, AbbVie will make tiered royalty payments based on global product sales to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

MAY 16, 2023

This comes with an upfront cash payment of $375 million, with a potential additional $25 million if Hemgenix net sales reach a certain milestone in 2024, based on a May 15 announcement. Additionally, UniQure was set to get tiered royalties of up to “a low-twenties percentage” of net product sales related to Hemgenix.

Gene Therapy 130

Gene Therapy Gene Sales Development 130

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52